Long-COVID-19 clinical and health outcomes: an umbrella review

Author:

Li Hu1ORCID,Xia Jin2,Bennett Dimitri23,Roque Fatima4ORCID,Bam Rujuta A.5,Tavares Ana Bárbara Tadeu4,Gokhale Mugdha67,Ida Fidelia8,Rhee Jinnie Jiwon9,Soriano Gabarro Montse10,Song Yiqing11

Affiliation:

1. Gilead Sciences Inc., 333 Lakeside Drive, Foster City, CA 94404, USA

2. Takeda Development Center Americas, Inc., Cambridge, MA, USA

3. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

4. Research Unit for Inland Development, Polytechnic of Guarda (UDI-IPG), Guarda, Portugal

5. Gilead Sciences Inc., Foster City, CA, USA

6. Pfizer Inc., New York, NY, USA

7. Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA

8. CSL Behring LLC, King of Prussia, PA, USA

9. Stanford University School of Medicine, Palo Alto, CA, USA

10. Bayer AG, Berlin, Germany

11. Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA

Abstract

Background: A growing interest in long-term sequelae of COVID-19 has prompted several systematic literature reviews (SLRs) to evaluate long-COVID-19 effects. However, many of these reviews lack in-depth information on the timing, duration, and severity of these conditions. Objectives: Our aim was to synthesize both qualitative and quantitative evidence on prevalence and outcomes of long-term effect of COVID-19 through an umbrella review. Design: Umbrella review of relevant SLRs on long-COVID-19 in terms of prolonged symptoms and clinical conditions, and comprehensively synthesized the latest existing evidence. Data Sources and Methods: We systematically identified and appraised prior systematic reviews/meta-analyses using MEDLINE, Embase, and Cochrane database of systematic review from 2020 to 2021 following the preferred reporting items for systematic reviews and meta-analyses guidance. We summarized and categorized all relevant clinical symptoms and outcomes in adults with COVID-19 using the Medical Dictionary for Regulatory Activities System Organ Class (MedDRA SOC). Results: We identified 967 systematic reviews/meta-analyses; 36 were retained for final data extraction. The most prevalent SOC were social circumstances (40%), blood and lymphatic system disorders (39%), and metabolism and nutrition disorder (38%). The most frequently reported SOC outcomes within each MedDRA category were poor quality of life (59%), wheezing and dyspnea (19−49%), fatigue (30−64%), chest pain (16%), decreased or loss of appetite (14–17%), abdominal discomfort or digestive disorder (12−18%), arthralgia with or without myalgia (16–24%), paresthesia (27%) and hair loss (14–25%), and hearing loss or tinnitus (15%). Conclusion: This study confirmed a high prevalence of several long COVID-19 outcomes according to the MedDRA categories and indicated that the majority of evidence was rated as moderate to low. Registration: The review was registered at PROSPERO ( https://www.crd.york.ac.uk/prospero/ ) (CRD42022303557).

Publisher

SAGE Publications

Subject

Pharmacology (medical),Infectious Diseases

Reference57 articles.

1. Long COVID: An overview

2. Characterising long COVID: a living systematic review

3. World Health Organization. Health emergency dashboard, https://covid19.who.int/ (2021, accessed May 2022).

4. Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK, https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021 (2021, accessed January 2023).

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3